AstraZeneca's tozorakimab shows success in COPD trials

AstraZeneca PLC's stock rose by 5.01% as it reached a 5-day high amid broader market declines.

The company's antibody therapy, tozorakimab, successfully met key goals in two Phase 3 trials for chronic obstructive pulmonary disease (COPD), demonstrating a significant reduction in annualized COPD exacerbations among over 2,000 patients. The trials showed that tozorakimab was generally well tolerated, which enhances AstraZeneca's competitiveness in the respiratory disease sector. The company is also conducting additional late-stage trials for tozorakimab and plans to present full results at an upcoming medical conference.

This positive trial outcome positions AstraZeneca favorably in the market, potentially leading to increased adoption of tozorakimab as a new therapeutic option for COPD patients.